Rexahn options RX3117 rights to Teva; deal terminated
Executive Summary
Rexahn Pharmaceuticals (oncology, CNS, and sexual dysfunction treatments) has granted Teva Pharmaceutical Industries, through its Teva Innovative Ventures partnering division, an exclusive option to license rights to develop and sell its RX3117 cancer candidate.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice